Here are the 10-Q quarterly reports from Nomad Power Solutions, Inc. (NMAD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NMAD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NMAD filings page.
NOMAD Power Solutions, Inc. completed a reverse acquisition on July 1, 2026, with NOMAD Transportable Power Systems as accounting acquirer; transportable power is now the company’s primary business. Legacy Lixte’s oncology and proton-therapy operations are included only from July 1. Conversion of Series D preferred shares into 50,366,070 common shares remains subject to Nasdaq approval of the new listing application and stockholder approval and had not occurred as of this report. Management intends to evaluate a disposition of the legacy life-sciences portfolio.
For the nine months ended September 30, 2026, sales were $1.093 million and net loss was $167.314 million, including $147.1 million of non-cash warrant charges and $6.4 million of merger-related costs. Net cash used in operating activities was $8.297 million. At September 30, cash was $5.649 million and the working-capital deficit was $4.765 million. A $6.57 million secured note issued September 28 produced $5.64 million in net proceeds and bears 9% annual interest.
Management said these conditions raise substantial doubt about the company’s ability to continue as a going concern within one year after the financial statements are issued.
Nomad Power Solutions, Inc. (formerly Lixte Biotechnology) reported no revenue for the three and six months ended June 30, 2026 and remains in the clinical-development stage. The company generated a Q2 2026 net loss of $2.34 million and a six‑month net loss of $4.33 million, compared with $0.78 million and $1.49 million in the prior-year periods, driven mainly by higher general and administrative expenses and increased research and development.
Cash increased to $12.67 million at June 30, 2026 from $5.11 million at December 31, 2025, primarily from a $16.57 million registered direct equity financing and warrant exercises, partly offset by $3.44 million of operating cash outflows and a $6.50 million secured note advanced to Nomad Transportable Power Systems ahead of a July 1, 2026 merger. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next 12 months due to ongoing losses, lack of revenue, and future funding needs for clinical programs and recommissioning of its LiGHT proton therapy system.